Epidermal growth factor (EGF) and transforming growth factor alpha (TG
F-alpha) are ligands for the EGF-receptor and act as mitogens for a va
riety of tissues. TGF-alpha, in particular, has been implicated as an
autocrine growth factor for several cancer cell lines. Over the last 1
0 years many groups have examined the structure-function relationships
in EGF/TGF-alpha in attempts to develop antagonists or agonists. In t
his review the results of these studies are summarised and related to
the three-dimensional structure of EGF/TGF-alpha. The difficulties ass
ociated with the purification and characterisation of analogues of EGF
/TGF-alpha and with the biological assays are discussed. It is clear t
hat these difficulties have, in some cases, led to apparently contradi
cting results. The available binding data indicate that the receptor i
nteraction surface for EGF/TGF-alpha might encompass one complete side
of the molecule with a few strong binding determinants, in particular
Arg41 and Leu47. The arginine at position 41 is the most critical res
idue and its full hydrogen-bonding capacity is needed for strong bindi
ng of EGF/TGF-alpha to the EGF-receptor. As this side of the molecule
consists of residues from both the N- and C-terminal domain, it seems
unlikely that agonists or antagonists can be developed on the basis of
short peptides taken from the primary sequence. This concept is suppo
rted by the available binding and activity data.